Clinical perspective: Biomarkers in pulmonary arterial hypertension

International Journal of Clinical Practice

Volumn 65, Issue SUPPL. 169, 2011, Pages 5-7

  Heresi, G A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARBON MONOXIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH DIFFERENTIATION FACTOR 15; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DIAGNOSTIC TEST ACCURACY STUDY; HEART CATHETERIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RIGHT HEART CATHETERIZATION; SCREENING; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; HEMODYNAMICS; IDIOPATHIC PULMONARY HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BIOLOGICAL MARKERS; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 78650836034     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02598.x     Document Type: Conference Paper

References (32)

1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Rich S,. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 2006; 130: 1198 - 202.
3. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037 - 47.
4. Rafeq S, Shah AM, Preston IR,. Biomarkers in pulmonary arterial hypertension. Int J Clin Pract 2009; 162: 36 - 41.
5. Allanore Y, Borderie D, Avouac J, et al. High n-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284 - 91.
6. Williams MH, Handler CE, Akram R, et al. Role of n-terminal brain natriuretic peptide (n-tprobnp) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485 - 94.
7. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 360 - 5.
8. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (bnp) and nt-probnp in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol. 2010; 37: 2064 - 70.
9. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers), endorsed by the international society of heart and lung transplantation (ishlt). Eur Heart J 2009; 30: 2493 - 537.
10. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865 - 70.
11. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (reveal). Circulation 2010; 122: 164 - 72.
12. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum n-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313 - 21.
13. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of n-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010; 35: 95 - 104.
14. Heresi GA, Aytekin M, Newman J, Dweik RA,. Cxc-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung 2010; 188: 191 - 7.
15. Tuder RM, Groves B, Badesch DB, Voelkel NF,. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275 - 85.
16. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, et al. Absence of t cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007; 175: 1280 - 9.
17. Quarck R, Nawrot T, Meyns B, Delcroix M,. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211 - 8.
18. Heresi GA, Aytekin M, Newman J, DiDonato J, Dweik RA,. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 661 - 8.
19. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 534 - 41.
20. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010; 122: 920 - 7.
21. Miura Y, Fukumoto Y, Sugimura K, et al. Identification of new prognostic factors of pulmonary hypertension. Circ J 2010; 74: 1965 - 71.
22. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (aries) study 1 and 2. Circulation 2008; 117: 3010 - 9.
23. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915 - 22.
24. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010; 29: 137 - 49.
25. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Eng J Med 1991; 324: 781 - 8.
26. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431 - 40.
27. Alonso A, Molenberghs G, Burzykowski T, et al. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 2004; 60: 724 - 8.
28. O'Quigley J, Flandre P,. Quantification of the prentice criteria for surrogate endpoints. Biometrics 2006; 62: 297 - 300.
29. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A,. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394 - 403.
30. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780 - 8.
31. Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP,. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009; 135: 137 - 42.
32. Pfisterer M, Buser P, Rickli H, et al. Bnp-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (time-chf) randomized trial. JAMA 2009; 301: 383 - 92.